X4 PHARMACEUTICALS INC (XFOR)
US98420X1037 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 60.49M | 99.22M | 121.70M | 81.80M | 78.70M | |||
| Marketable Securities | 20.38M | 15.00M | N/A | N/A | N/A | |||
| Receivables | 702.00K | 562.00K | 1.20M | 700.00K | 900.00K | |||
| Other Current Assets | 5.76M | 7.30M | 5.80M | 5.30M | 3.70M | |||
| Total Current Assets | 87.33M | 122.08M | 128.70M | 87.90M | 83.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 6.01M | 6.39M | 8.30M | 10.20M | 9.20M | |||
| Goodwill | 17.35M | 17.35M | 17.40M | 17.40M | 27.10M | |||
| Other Non-Current Assets | 1.49M | 1.44M | 1.20M | 1.70M | 3.30M | |||
| Total Non-Current Assets | 24.85M | 25.18M | 26.90M | 29.30M | 39.60M | |||
| TOTAL ASSETS | 112.18M | 147.26M | 155.60M | 117.20M | 122.90M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | 0.00 | 1.30M | 800.00K | N/A | |||
| Accrued Expenses | 14.61M | 13.91M | 13.20M | 8.90M | 8.80M | |||
| Accounts Payable | 8.94M | 8.95M | 7.80M | 4.30M | 3.10M | |||
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | |||
| Total Current Liabilities | 23.54M | 22.86M | 22.30M | 14.00M | 11.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 54.82M | 54.57M | 32.30M | 33.10M | 33.20M | |||
| Other Non-Current Liabilities | 32.78M | 18.73M | 26.90M | 5.60M | 4.90M | |||
| Total Non-Current Liabilities | 87.61M | 73.30M | 59.20M | 38.80M | 38.20M | |||
| TOTAL LIABILITIES | 111.15M | 96.16M | 81.50M | 52.80M | 50.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -529.67M | -477.90M | -376.70M | -282.90M | -194.20M | |||
| Additional Paid In Capital | 530.69M | 528.96M | 450.80M | 347.40M | 267.10M | |||
| Common Shares | 168.00K | 167.00K | 100.00K | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -155.00K | -119.00K | -100.00K | -100.00K | -100.00K | |||
| Shares Outstanding | 167.94M | 167.43M | 121.70M | 28.10M | 16.30M | |||
| Tangible Book Value per Share | -0.10 | 0.20 | 0.47 | 1.67 | 2.80 | |||
| Total Shareholders' Equity | 1.04M | 51.10M | 74.10M | 64.40M | 72.80M | |||
| TOTAL LIABILITIES AND EQUITY | 112.18M | 147.26M | 155.60M | 117.20M | 122.90M | |||
| Statistics | ||||||||
| Debt/Equity | 52.92 | 1.07 | 0.44 | 0.51 | 0.46 | |||
| Current Ratio | 3.71 | 5.34 | 5.77 | 6.28 | 7.00 | |||
| Return On Assets (ROA) | -114.92% | -68.70% | -61.96% | -87.58% | -50.55% | |||
| Return On Equity (ROE) | -12443.63% | -197.98% | -130.11% | -159.38% | -85.34% | |||
All data in USD